<DOC>
	<DOCNO>NCT00425477</DOCNO>
	<brief_summary>RATIONALE : Bexarotene may help cancer abnormal cell become like normal cell , grow spread slowly . Colony-stimulating factor , GM-CSF , may increase number immune cell find bone marrow peripheral blood . Giving bexarotene together GM-CSF may effective treatment myelodysplastic syndrome ( MDS ) acute myeloid leukemia . PURPOSE : This phase II trial study well give bexarotene together GM-CSF work treat patient MDS acute myeloid leukemia .</brief_summary>
	<brief_title>Bexarotene GM-CSF Treating Patients With Myelodysplastic Syndrome Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess clinical response patient myelodysplastic syndrome acute myeloid leukemia treat bexarotene sargramostim ( GM-CSF ) . Secondary - Determine clinical activity regimen , term transfusion requirement , patient . - Determine biological activity regimen , term biological marker cytogenetic abnormality , patient . - Assess toxicity profile regimen patient . OUTLINE : Patients receive oral bexarotene sargramostim ( GM-CSF ) subcutaneously day 1-28 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Blood bone marrow sample collect baseline 1 2 course study therapy . Samples examine flow cytometry laboratory study , include biological marker , fluorescent situ hybridization ( FISH ) cytogenetic change . After completion study treatment , patient follow periodically 6 month . PROJECTED ACCRUAL : A total 18 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Bexarotene</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis ( confirm bone marrow aspirate and/or biopsy ) 1 follow : Myelodysplastic syndrome 1 follow cell type : Refractory anemia ( RA ) ring sideroblast Refractory cytopenia multilineage dysplasia ( RCMD ) RCMD ring sideroblast RA excess blasts1 RA excess blasts2 Myelodysplastic syndrome , unclassified Chronic myelomonocytic leukemia Relapsed refractory acute myeloid leukemia ( AML ) , meet 1 follow criterion : Recurrent genetic abnormality ( 11q23 [ MLL ] abnormality ) Multilineage dysplasia Therapyrelated AML Not otherwise categorize , include follow : M0 minimally differentiate M1 without maturation M2 maturation M4 myelomonocytic leukemia M5 monoblastic/monocytic leukemia M6 erythroid leukemia M7 megakaryoblastic leukemia Newly diagnose untreated AML allow provide patient qualify refuse potentially curative intensive chemotherapeutic regimens No RA 5qsyndrome No peripheral leukemia blast count &gt; 30,000/mm³ ( uncontrolled hydroxyurea ) Relatively stable bone marrow function &gt; 7 day ( i.e. , WBC double &gt; 10,000/mm^3 ) No acute promyelocytic leukemia No clinical symptom active CNS disease ( CNS disease suspect , patient must lumbar puncture negative cytology ) PATIENT CHARACTERISTICS : ECOG performance status 02 Creatinine ≤ 2.0 mg/dL Bilirubin ≤ 1.6 mg/dL ( unless secondary hemolysis ) AST ALT ≤ 4 time upper limit normal ( unless disease relate ) Hemoglobin ≥ 8 g/dL ( transfusion allow ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception No untreated positive blood culture progressive infection assess radiographic study No history intolerance sargramostim ( GMCSF ) PRIOR CONCURRENT THERAPY : Recovered prior therapy At least 2 week since prior treatment myeloid disorder , include follow : Chemotherapy Hematopoietic growth factor Biologic therapy ( e.g. , monoclonal antibody ) Hydroxyurea patient WBC &gt; 10,000/mm^3 allow No concurrent vitamin A supplementation No concurrent gemfibrozil</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory cytopenia multilineage dysplasia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
</DOC>